Levoketoconazole is a Small Molecule owned by Strongbridge Biopharma, and is involved in 8 clinical trials, of which 7 were completed, and 1 is ongoing.

Levoketoconazole (COR-003) acts by inhibiting 11-beta-hydroxylase enzyme, the terminal step in cortisol synthesis in the adrenal gland and lowers the LDL-cholesterol. It also inhibits 14-alpha-demethylase, a key enzyme in cholesterol synthesis.The drug candidate by inhibiting cortisol production exerts therapeutic intervention.

The revenue for Levoketoconazole is expected to reach a total of $3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Levoketoconazole NPV Report.

Levoketoconazole is currently owned by Strongbridge Biopharma. Xeris Biopharma Holdings is the other company associated in development or marketing of Levoketoconazole.

Levoketoconazole Overview

Levoketoconazole (Recorlev) is a imidazole derivative, acts as an anti-fungal agent. It is formulated as tablets for oral route of administration. Recorlev is indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.

Xeris Biopharma Holdings Overview

Xeris Biopharma Holdings (XERIS) is the specialty pharmaceutical company that develops novel technology platforms to develop and commercialize stable injectable and infusible drug formulations. The company’s XeriSol formulation technology enables the subcutaneous and intramuscular delivery of concentrated formulations of proteins, peptides, antibodies and small molecules using syringes, multi-dose pens, auto-injectors and pumps. XERIS’s products are used in therapeutic areas such as severe hypoglycemia, post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure, exercise-induced hypoglycemia, acute repetitive seizures and type 1/type 2 blood sugar controls. It caters to caregivers, health practitioners and patients. XERIS is headquartered in Chicago, Illinois, the US.

The company reported revenues of (US Dollars) US$49.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$20.4 million in FY2020. The operating loss of the company was US$115.2 million in FY2021, compared to an operating loss of US$84.3 million in FY2020. The net loss of the company was US$122.7 million in FY2021, compared to a net loss of US$91.1 million in FY2020. The company reported revenues of US$29.7 million for the third quarter ended September 2022, an increase of 17.5% over the previous quarter.

Quick View – Levoketoconazole

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Levoketoconazole
Administration Pathway
  • Oral
Therapeutic Areas
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.